Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.

Antonio DonoMark AmsbaughMagda MartirRichard H SmilieRoy F RiascosJay-Jiguang ZhuSigmund HsuDong H KimNitin TandonLeomar Y BallesterAngel I BlancoYoshua Esquenazi

Published in: Journal of neuro-oncology (2021)

SRS is a safe and effective treatment option for selected rGBM-IDH-WT patients following first recurrence. rGBM-IDH-WT harboring PTEN-mutation have improved survival with salvage SRS compared to PTEN-WT patients. PTEN may be used as a molecular biomarker to identify a subset of rGBM patients who may benefit the most from SRS.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
cell proliferation
prognostic factors
small cell lung cancer
patient reported outcomes
brain metastases
high grade
smoking cessation